Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) today announced that it has entered into a definitive license agreement with PharmAla Biotech Holdings Inc. for perpetual exclusive U.S. rights to ALA-002. The transaction has a potential value of up to $100 million, including milestone payments, and expands Jupiter from a single-program company into a dual clinical-stage CNS developer. Management believes the transaction strengthens the Company through diversification across two-clinical-stage CNS assets; expanding its portfolio to include both its natural resveratrol program and a Novel Chemical Entity; near term clinical milestones; and long-term participation in U.S commercialization opportunity through perpetual exclusive rights.

Transaction Highlights Deal Value: Up to $100M (including milestone payments; exclusive of ongoing royalties) Upfront Payment: $3.3M ($1.5M cash + $1.8M JUNS common stock, 120-day lock-up) Development Milestone: $3.3M upon Phase 3 First Patient In Regulatory Milestone: $20M upon U.S. NDA Approval Commercial Milestones: $10M / $30M / $33.3M at $333M / $1B / $2B cumulative U.S. net sales Royalty: 3% of net sales (commencing after third commercialization milestone)

Asset: ALA-002 — FDA NCE-designated, non-racemic MDMA (patented) Rights Granted: Perpetual, exclusive to United States

About ALA-002 ALA-002 is a patented, non-racemic MDMA formulation that has received Novel Chemical Entity (NCE) designation from the U.S. Food and Drug Administration (FDA), providing enhanced regulatory protection and a five-year data exclusivity period upon approval. ALA-002 has been engineered to deliver materially improved cardiovascular safety and reduced abuse liability compared to racemic MDMA while preserving the pro-social and therapeutic properties central to MDMA-assisted psychotherapy. PharmAla’s MDMA supply is currently active in U.S. government-sponsored VA and DHA clinical trials. ALA-002 targets a U.S. psychedelic therapeutics market estimated at $3 B in 2024 and growing to $8 B by 2030 (source: Strategic Market Research), addressing millions of Americans living with treatment-resistant PTSD, anxiety, and related neuropsychiatric conditions.

GMP Drug Supply PharmAla is a globally recognized manufacturer and supplier of MDMA for clinical use, with supply contracts for clinical trials on 3 continents, and serving such institutions as the US Veterans Affairs Administration and several Ivy League universities. Under the terms of the Definitive Agreement, PharmAla will continue to manufacture ALA-002 drug product for Jupiter under commercial terms to be negotiated, greatly accelerating Jupiter’s development timelines.

Executive Order and Regulatory Alignment On April 18, 2026, President Donald J. Trump signed a landmark Executive Order titled “Accelerating Medical Treatments for Serious Mental Illness,” directing the FDA and DEA to expand access to investigational psychedelic therapies. Key provisions include: a Right to Try pathway for eligible patients; Commissioner’s National Priority Vouchers enabling 1–2 month expedited FDA review timelines for psychedelic drugs with Breakthrough Therapy designation; and $50M in federal funding through ARPA-H for state and federal psychedelic medicine programs. Jupiter’s acquisition of exclusive U.S. rights to ALA-002 directly leverages this regulatory acceleration, which management believes may allow the Company to benefit from an evolving re...